Share on StockTwits

Foundation Medicine (NYSE:FMI) CEO Michael J. Pellini sold 15,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $27.42, for a total value of $411,300.00. Following the completion of the sale, the chief executive officer now directly owns 510,000 shares in the company, valued at approximately $13,984,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Foundation Medicine (NYSE:FMI) opened at 29.30 on Friday. Foundation Medicine has a 52-week low of $19.513 and a 52-week high of $45.00. The stock has a 50-day moving average of $23.71 and a 200-day moving average of $28.47. The company’s market cap is $826.0 million.

Foundation Medicine (NYSE:FMI) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.44) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.48) by $0.04. The company had revenue of $11.45 million for the quarter, compared to the consensus estimate of $11.33 million. Foundation Medicine’s revenue was up 120.2% compared to the same quarter last year. Analysts expect that Foundation Medicine will post $-1.82 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday, June 25th. They set a “neutral” rating and a $28.00 price target on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th. Finally, analysts at William Blair initiated coverage on shares of Foundation Medicine in a research note on Thursday, April 17th. They set a “market perform” rating on the stock. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Foundation Medicine presently has an average rating of “Hold” and an average price target of $38.80.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Stay on top of analysts' upgrades and downgrades with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' ratings changes. Register Now.